Company Overview of Alvogen, Inc.
Alvogen, Inc. engages in the product development, contract manufacturing and research, and sale of generic and brand medicines, biosimilars, and OTC products. Its product portfolio comprises a range of molecules for the treatment of conditions in the areas of oncology, cardiology, respiratory, neurology, and gastroenterology. The company focuses on niche generics, patches, controlled release, and narcotics in the form of solid oral dosage, soft gelatin capsules, modified release tablets, transdermals, creams, ointments, and injectables; promotes and distributes various biosimilar products for indications across several therapeutic areas; provides contract manufacturing, product development, ...
10 Bloomfield Avenue
Pine Brook, NJ 07058
Founded in 2008
Key Executives for Alvogen, Inc.
Executive Chairman and Chief Executive Officer
Executive Vice President of Global Supply Chain
Chief Financial Officer and Member of Executive Board
Chief Operating Officer and Member of Executive Board
Member of Executive Board and Chief Executive Officer of Alvogen America
Compensation as of Fiscal Year 2015.
Alvogen, Inc. Key Developments
Alvogen, Inc. Presents at Jefferies 2014 Global Healthcare Conference: London, Nov-20-2014 10:00 AM
Nov 19 14
Alvogen, Inc. Presents at Jefferies 2014 Global Healthcare Conference: London, Nov-20-2014 10:00 AM. Venue: The Waldorf Hilton, Aldwych, London, United Kingdom.
Alvogen, Inc. Presents at UBS Global Healthcare Conference, May-19-2014
Apr 17 14
Alvogen, Inc. Presents at UBS Global Healthcare Conference, May-19-2014 . Venue: Sheraton New York Times Square Hotel, 811 Seventh Avenue, New York, New York, United States.
Alvogen, Inc. Announces Launch of InflectraTM) (Infliximab) into Central and Eastern Europe
Feb 13 14
Alvogen, Inc. announced the launch of Inflectra(TM) (Infliximab) into Central and Eastern Europe. Inflectra(TM), Europe's first biosimilar monoclonal antibody (mAb) therapy that has been approved for the treatment of inflammatory conditions including rheumatoid arthritis (RA), ankylosing spondylitis, Crohn's disease (CD), ulcerative colitis (UC), psoriatic arthritis (PsA) and psoriasis. Alvogen and Hospira formed a strategic partnership in 2011 to provide the quality products and services for customers and patients throughout Central and Eastern Europe (CEE). This alliance enables to provide increased access to the newest biosimilar drugs with technology. Inflectra(TM) is a biosimilar medicine to the reference medicinal product, Remicade(TM) (Infliximab), and is the first monoclonal antibody (mAb) to be approved through the European Medicines Agency (EMA) biosimilars regulatory pathway. Remicade(TM) recorded European sales of over USD 2 billion in 2012. Alvogen will market the product in Bulgaria, Croatia, Estonia, Hungary, Latvia, Lithuania, Poland, and Romania. The use of biologic medicines has led to vast improvements in the efficient treatment of conditions such as RA and IBD (inflammatory bowel disease), but these drugs are also responsible for some of the medicinal costs for many countries. The introduction of biosimilar mAbs in Europe is expected to deliver savings of up to EUR 20.4 billion by 2020. In partnership with Hospira, Alvogen has been marketing biosimilars in Central & Eastern Europe for a number of years, with great success. Partnering with Hospira gives Alvogen access to a well established biosimilar pipeline. Hospira's biosimilar portfolio includes Inflectra(TM) as well as two other currently marketed products in the areas of nephrology and oncology. In addition, Hospira plans to launch a number of new biosimilar monoclonal antibodies, one of which is currently in late stage development. Together, Alvogen and Hospira share the commitment to deliver the quality products and services to its customers and patients.
Similar Private Companies By Industry
Recent Private Companies Transactions
June 22, 2015